TWC
BDTX icon

TD Waterhouse Canada’s Black Diamond Therapeutics BDTX Stock Holding History

TD Waterhouse Canada’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$729 – 2317
2025
Q4 		$729 Hold
300
– – ﹤0.01% 1898
2025
Q3 		$1.12K Hold
300
– – ﹤0.01% 1888
2025
Q2 		$743 Buy
+300
New +$578 ﹤0.01% 1828

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TD Waterhouse Canada's BDTX Position: Q1 2026 in Review

TD Waterhouse Canada sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 300 shares — an estimated $729 sold.

TD Waterhouse Canada first reported a position in BDTX in Q2 2025 and held it in 3 quarters. The position peaked at $1.12K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • TD Waterhouse Canada reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TD Waterhouse Canada sold 300 Black Diamond Therapeutics shares in Q1 2026, an estimated $729.
  • TD Waterhouse Canada first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 3 quarters.
  • TD Waterhouse Canada's Black Diamond Therapeutics position peaked at $1.12K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.